HGH Injections For Sale

Human growth hormone (hGH) Testing | World Anti-Doping Agency

The concepts and development of both hGH tests have been systematically reviewed by international independent experts in such fields as hGH and IGF-I, endocrinology, immunoassay, analytical chemistry, pharmacology, laboratory work, anti-doping, etc., and published in international scientific journals.

The 2013 Court of Arbitration for Sport (CAS) decision on the FIS vs. Veerpalu case confirmed that the current Isoforms Test is robust and scientifically reliable. As a result of criticism expressed by the CAS Panel on the statistical procedure originally applied to the determination of the tests DLs, new statistical analyses were performed on an increased number of hGH doping control data (samples from athletes treated under real doping control conditions of sample collection, transportation, storage and analysis, including standardized analytical protocols and instrumentation) by two independent teams of statisticians. The results of the study have been published in an independent peer-reviewed scientific journal specialized in GH and IGF-I research.

The revised DLs have been incorporated into a new version of the Guidelines on hGH Isoform Differential Immunoassays for anti-doping analyses, available on WADAs website.These Guidelines continue to provide direction on the sample pre-analytical preparation procedure, the performance of the test and the interpretation and reporting of the test results.

For more information on the process followed to determine the tests DLs, please consult Hanley JA et al. hGH isoforms differential immunoassays applied to blood samples from athletes: decision limits for anti-doping testing. Growth Hormone & IGF Research, 2014.

The scientific validity and efficacy of the hGH biomarkers approach has been documented in multiple scientific publications for over a decade. A series of placebo-controlled recombinant recGH administration studies performed in Europe and Australia has shown that both IGF-I and P-III-NP rise substantially following recGH administration in a dose-dependent manner. These markers have been evaluated for several confounding factors that might influence the scores of the discriminant functions, including age, gender, ethnicity, exercise, diurnal and day-to-day variation, intra-individual variation, bony and soft tissue injury, sporting discipline, and body habitus (physique). Nevertheless, before resuming its implementation in WADA-accredited laboratories, the study on the determination of the DLs for the new assays will be also subjected to independent peer review and publication in an international scientific journal.

See more here:

Human growth hormone (hGH) Testing | World Anti-Doping Agency

2688 – Gene ResultGH1 growth hormone 1 [ (human)]

NEW Try the new Transcript table

These reference sequences exist independently of genome builds. Explain

These reference sequences are curated independently of the genome annotation cycle, so their versions may not match the RefSeq versions in the current genome build. Identify version mismatches by comparing the version of the RefSeq in this section to the one reported in Genomic regions, transcripts, and products above.

NG_011676.1RefSeqGene

NM_000515.5 NP_000506.2 somatotropin isoform 1 precursor

See identical proteins and their annotated locations for NP_000506.2

Status: REVIEWED

NM_022559.4 NP_072053.1 somatotropin isoform 2 precursor

See identical proteins and their annotated locations for NP_072053.1

Status: REVIEWED

NM_022560.4 NP_072054.1 somatotropin isoform 3 precursor

See identical proteins and their annotated locations for NP_072054.1

Status: REVIEWED

The following sections contain reference sequences that belong to a specific genome build. Explain

This section includes genomic Reference Sequences (RefSeqs) from all assemblies on which this gene is annotated, such as RefSeqs for chromosomes and scaffolds (contigs) from both reference and alternate assemblies. Model RNAs and proteins are also reported here.

NC_000017.11Reference GRCh38.p13 Primary Assembly

The following Reference Sequences have been suppressed. Explain

These RefSeqs were suppressed for the cited reason(s). Suppressed RefSeqs do not appear in BLAST databases, related sequence links, or BLAST links (BLink), but may still be retrieved by clicking on their accession.version below.

NM_022561.2: Suppressed sequence

NM_022562.2: Suppressed sequence

Read this article:

2688 - Gene ResultGH1 growth hormone 1 [ (human)]

Human Growth Hormone for Men: Facts, Benefits, Chart …

Human growth hormone HGH for men is vital for optimal health physically, mentally, emotionally and sexually. In fact, both sexes, men and women need balanced levels of growth hormone in order look and feel their best.

As aging takes its course, many men may start to notice the very apparent signs and symptoms of a growth hormone deficiency that is caused by growing older. When they start to lose their growth hormone, they may be able to see first-hand that HGH for male bodies is just as important as other hormones such as testosterone.

HGH for mens health is something that needs more attention from professionals in the medical field. Growth hormone (GH) plays an important role in keeping a man looking and feeling youthful as the years pass. Properly balanced levels of GH in a mans system, along with living a healthy lifestyle can keep him optimally healthy throughout his life.

The pituitary gland is responsible for the production of growth hormone in men. This gland is located at the base of the brain. Like all other organs, it slows down as it ages. When the pituitary slows down, so does its production of GH and this is when signs and symptoms of a deficiency may begin.

The proper amount of growth hormone production from the pituitary gland is vital for good health. This is why growth hormone for men in the form of bio-identical injections is so important and popular. Properly prescribe HGH injections can accurately increase the amount of human growth hormone within the body so that a man can feel great, healthy and strong.

Studies have shared information that keeping growth hormone levels at a healthy level can slow down the disease of Alzheimers. This can dramatically extend quality of life.

Lastly, in regards to what HGH can do for men, it is important to remember that not all men will experience the same benefits from HGH injections. All people will have different symptoms, body chemistry and body composition that will determine what HGH will do for them.

On the other hand, many benefits such as increased energy and less apathy with a better outlook on life can occur for most people. HGH injections must be properly prescribed by a licensed doctor and taken with medical supervision.

Experts have agreed upon different GH levels to be normal, low, and high in men. Different sources will show varying levels of growth hormone to be too low, too high or normal. In this case, a man should not be overly concerned if he falls slightly out of normal range for his GH levels according to one chart vs. another.

On the other hand, if GH levels do fall greatly below normal range, the man may benefit greatly from HGH for men for sale. Human growth hormone injections must be prescribed and taken only with medical supervision for them to be legal and safe at the same time.

HGH Levels In Men: A Chart

Again, remember that if your levels fall out of the range considered normal as referenced above, do not panic. Talking to your doctor about how your growth hormone levels may be affecting you is your first line of defense against poor health. The easiest way to help men with GH deficiencies is by getting the proper prescription for 100 natural and authentic HGH by a licensed doctor.

When blood testing reveals that a man has a GH deficiency, help is here. Human growth hormone levels in men can be raised very safely. When prescribed and taken correctly, the right HGH medication can produce remarkable benefits that can give a man back the good health and happiness they had before Mother Nature took over and aged his body.

Growth hormone declines with age because as all organ and glands in the body slow down, so does the main gland that produces GH; the pituitary gland. The explanation as to why men lose their growth hormone as the years pass by is simple aging.

Usually at around the age of 30 (some men can be older), the body starts to feel the signs and symptoms of aging. Even if a person cannot actually see or feel their bodies transforming, their internal organs, cells, tissues and glands are indeed changing.

As all body parts get older comes the slowing down of their functioning. Since the pituitary gland is mainly responsible for producing hormone (growth hormone being one), GH and other hormones will slowly deplete as the man grows older and older.

HGH for men over 30, HGH for men over 40 and HGH for men over 50 or even older can be extremely beneficial. Males under 30 are usually never prescribed human growth hormone medication for issues that have to do with the aging process. Most experts do not believe that a man will start to experience the signs and symptoms of a GH depletion until they are over 30.

How can a man become a part of HGH therapy for men? It all begins with a simple phone call to a clinical advisor at the hormone replacement therapy clinic of the mans choice. Our clinic is always very happy to discuss with new potential patients the process of HGH therapy for men, testing, what to expect from therapy and what the benefits are of this kind of treatment.

In addition, clinical advisors will be the first experts from the clinic to want to know what symptoms a man is experiencing, what treatment he has had in the past and what his goals are for HGH therapy at the time of his call.

Together as a team, the advisor and the caller will identify the different reasons the man may be experiencing symptoms. If the reasons seem like they are being caused from a GH deficiency, blood testing can take place to find out if GH levels in the body are too low. Then HGH therapy for men can become what helps the male to become stronger, healthier and happier about his future ahead.

For more information about human growth hormone for men, please reach out to us. Our contact form is right here on this page online. It takes just a few minutes to fill out and you can be speaking with an expert about how HGH therapy can help to change your life and your future for the better.

See the rest here:

Human Growth Hormone for Men: Facts, Benefits, Chart ...

Growth Hormone Deficiency – NORD (National Organization …

Congenital GHD results from genetic error, and may be associated with brain structure defects or with midline facial defects such as a cleft palate or single central incisor.

Several genetic defects have been identified:

Growth hormone deficiency IA is autosomal recessive and is characterized by growth retardation in utero. Affected children are small in relation to their siblings. The infant usually has a normal response to administration of human growth hormone (hGH) at first, but then develops antibodies to the hormone and grows into a very short adult.

Growth Hormone Deficiency IB is also autosomal recessive and is similar to IA. However, there is some growth hormone (GH) present in the child at birth and usually the child continues to respond to hGH treatments.

Growth Hormone Deficiency IIB and III are similar to IB, but IIB is autosomal dominant and III is X-linked.

Classic genetic diseases are the product of the interaction of two genes, one received from the father and one from the mother.

Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.

Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy.

The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.

Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk of having children with a recessive genetic disorder.

X-linked genetic disorders are conditions caused by an abnormal gene on the X chromosome and manifest mostly in males. Females that have a defective gene present on one of their X chromosomes are carriers for that disorder. Carrier females usually do not display symptoms because females have two X chromosomes and only one carries the defective gene. Males have one X chromosome that is inherited from their mother and if a male inherits an X chromosome that contains a defective gene he will develop the disease.

Female carriers of an X-linked disorder have a 25% chance with each pregnancy to have a carrier daughter like themselves, a 25% chance to have a non-carrier daughter, a 25% chance to have a son affected with the disease and a 25% chance to have an unaffected son.

If a male with X-linked disorders is able to reproduce, he will pass the defective gene to all of his daughters who will be carriers. A male cannot pass an X-linked gene to his sons because males always pass their Y chromosome instead of their X chromosome to male offspring.

Acquired GHD can occur as a result of many different causes including brain trauma (perinatal or postnatal), central nervous system infection, tumors of the hypothalamus or pituitary (pituitary adenoma, craniopharyngioma, Rathkes cleft cyst, glioma, germinoma, metastases), radiation therapy, infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis, tuberculosis), or, if without another diagnosis, it is considered idiopathic.

See the original post here:

Growth Hormone Deficiency - NORD (National Organization ...

Learn to let go of sleep battles with your teen – WTVA

It's 11 p.m. on a school night, and the light is still pouring out from under your teen's door. You do some quick math. If they fall asleep ... NOW ... they'll get just under 6.5 hours of sleep before they have to be up and out the door.

That's definitely not enough, but what can you do? Hold their eyelids closed? If it were that easy, we'd all have tried.

It is one of the great frustrations and ironies of parenting that getting your child to do something so necessary, unavoidable and pleasurable as sleep has to also be a daily battle.

In my work with teens for the past 15 years, and in my own experience as a parent, I've seen and engaged in these battles firsthand. It's caused me to wonder why we adults have so many strong emotions invested in our how our kids sleep?

It starts at birth. "Sleep is one of the first markers of whether or not you're nailing it as a parent," explained psychologist Kristin Daley, who serves as chair of the national clinical practice committee for the Society for Behavioral Sleep Medicine.

Over the past 20 years, Daley said sleep has become an even more emotionally loaded issue for families. "Along with the idea that we should have it all, we now have comparisons," Daley said, and often those comparisons leave us feeling we're falling short.

Parents don't just put their kids to bed, wring their hands and hope they're doing it right. Now they put those hands to work, scrolling through family lifestyle accounts on Instagram, parenting groups on Facebook and mom blogs, finding a stream of cheerful advice and peaceful photos of sleeping kiddos with fresh-faced parents gazing over them appreciatively.

"Sleep is an area of health and medicine that's strongly politicized," Daley said. "You have the attachment parenting people and the rigorous sleep training crowd, and so starting from infancy there is a marker of 'how I'm doing as a parent can be seen in how regulated my kid is.'"

This feeling doesn't go away once our kids start sleeping through the night. There may be a reprieve in bedtime battles and parental insecurity for a short time until kids hit puberty.

"I know she'd do better if she would just sleep more!" says the tired parent. "This is just one more area of my life you want to control!" says the independence-seeking teen.

Scenes like this play out all the time in Daley's private practice. As an expert in adolescent sleep, Daley advises clients, "don't fight what you can't control." You can't change a person's biological clock. Circadian rhythm -- the internal clock that tells you when to be awake and when to get sleepy -- shifts during early adolescence, turning even formerly great sleepers into night owls.

But you can optimize the environment for more success.

The biggest impact on your child's sleep may surprise you. More than weighted blankets, blackout curtains, limited access to electronics, or temperature-controlled bedrooms -- all of which can certainly help -- the single thing that has the greatest influence on a young child's healthy sleep habits is how much a parent prioritizes, values and is consistent with sleep in the home, according to a 2016 study.

That means if you protect the time and environment around bedtime, your child is more likely to reap the benefits of good sleep, of which there are many. In addition to renewed energy and mood, Daley said that long exposure to sleep during dark hours is what optimizes human growth hormone.

Got a teen who wants to be taller? This may be the one approach that convinces your child that sleep is worthwhile.

Scheduling is critical. Kids who don't get home from extracurricular activities until well after dinner, still needing to eat and do homework, are at a big disadvantage for meeting their sleep requirements. Valuing sleep as a parent often means making hard choices when you also value sports, theater, grades or family time.

It's not just nighttime schedules that matter. A consistent wake time, exposure to light and a good breakfast send signals to the brain that it's time to get moving, even when school's start doesn't align with your teen's new circadian clock. Those are the natural ways our bodies regulate time. And of course, devices in rooms are notorious for pushing a teen's normal schedule much later than is healthy. Watching TV across the room is not bad for a teen near bedtime, Daley said, but a light source that is 18 inches or less from eyeballs will really interfere with a teen's ability to fall asleep.

Here is one final thing you can control: your mood, health and well-being. These are huge factors in your child's relationship to healthy sleep. Prioritize your own sleep, and your kids will eventually follow suit.

While teens are much more resilient when it comes to sleep loss, Daley says a night or two of bad sleep can derail a parent for much longer than it would a teen. Leave your devices out of the bedroom, shut the door and get the sleep you need, first and foremost. You'll be a happier person, and your child will probably thank you for it.

See more here:

Learn to let go of sleep battles with your teen - WTVA

HGH and Sport celebrities: Why they use HRT – The Sports Bank

When playing sports professionally and competitively, many athletes rely on HGH. HGH is shown to improve the athletic performance of men and women who play sports for those who suffer from hormone deficiency. There are a few main reasons why sports celebrities rely on HRH to play well, which has contributed to its popularity and success in recent years.How Older Adults Can Benefit From the Growth HormoneHRT is provided to patients who need hormone therapy due to a deficiency in their bodies. When used routinely, it can treat a variety of conditions like menopause and is necessary for reducing the risk of different ailments and diseases that can occur over time. This makes it one of the main reasons its commonly prescribed to older adults. It is also prescribed to older men who experience a lower production of testosterone as they age.HRT is known to contain female hormones and works well for replacing estrogen, which the body naturally stops producing during menopause. Stories of Sportsmen Using HGHPeyton Manning is one of the most well-known athletes in the world that used HGH, which was sent to his home in Florida in 2015. Manning claimed that the hormones were used as a treatment for a condition his wife suffered from, but this was never confirmed. Eventually, the NFL cleared Manning due to a lack of credible evidence.Baseball players Ryan Zimmerman and Philadelphia Phillies Ryan Howard were also found to take performance-enhancing drugs. Lance Armstrong admitted to using EPO, testosterone, and blood transfusions, which contributed to his performance and ability to win the Tour de France seven times.

Cyclist Floyd Landis was also stripped of his Tour de France title once he failed a drug test. The medication was used to raise their blood, but this can lead to thickened blood that prevents it from circulating correctly. Over time, this can gradually lead to cardiovascular issues.Why is HGH Used in Professional Sports?Many athletes use HGH in sports to increase their stamina, which helps them to perform better and longer while competing professionally. Prohibited steroid hormones are often prescribed for those who want a boost in their stamina and treat general fatigue that they may be experiencing.Hormones are also used by athletes because they work well to help their bodies adapt to more challenging exercise routines as they start to put more stress on their bodies. Theyre effective in stimulating different types of proteins and help to build more muscle mass. Theyre also proven to synthesize enzymes, which help to build the bodys endurance levels.Some of the hormone treatment therapies like testosterone and dehydroepiandrosterone are prohibited by the World Anti-Doping Agency for athletes who participate competitively. The hormones are prohibited regardless of if theyre natural, synthetic, or bioidentical. It doesnt matter how theyre marketed or used. Even if athletes are attempting to increase their hormone levels to bring them back to normal, they are still prohibited with the anti-doping rules that are currently in place. The list of performance-enhancing substances that are approved by the World Anti-Doping Agency continues to become shorter over time. This limits the options available to athletes who are looking for ways to improve their health, especially if they have a hormonal imbalance. Male athletes are also not provided exemptions at the Olympics. In six years, the Major League Baseball Association has only provided athletes with a total of six exemptions out of 1,200 baseball players. However, there are not any watchdogs that exist to keep players accountable to avoiding the use of HRT. Negative Effects for AthletesAlthough there has been a lot of success with HRT, there are still some risks involved that patients should be aware of in advance while working with a medical professional. The type of hormone therapy influences the risks, as well as the specific dose that is prescribed. This makes it necessary for the hormones to be tailored depending on the individual, their specific needs, and their history. A medical professional should also monitor the results of the hormone therapy and make any necessary adjustments. Sermorelin dosage, as one of the most commonly prescribed HGH brands, should be strictly prescribed by professional Endocrinologist, to prevent abuse.Studies show theres an effect of HRT on the body, like any type of medication. Athletes who are prescribed estrogen may experience bloating, indigestion, leg cramps, vaginal bleeding, breast tenderness, headaches, and can feel sick or unwell. Some of the symptoms may begin to subside after the first two weeks of taking the medicine. The medical professional may recommend taking the medicine with food to reduce indigestion or nausea. Its also suggested to regularly stretch and exercise for those who begin to experience leg cramps. Eating a diet that has low carbohydrates and fat can be beneficial to reduce breast tenderness. If the side effects continue, the medical professional will likely prescribe a different type of medication.Theres also a risk of side effects for those who are prescribed progestogen, which includes swelling in various parts of the body, vaginal bleeding, abdominal and/or back pain, acne, breast tenderness, mood swings, and headaches or migraines. Similar to estrogen, the symptoms typically subside after several weeks of taking the medication consistently. Athletes may notice that they begin to experience weight gain after several weeks of taking HRT, especially if theyre going through menopause. Eating a healthy diet and continuing to exercise can minimize the weight gain and allow the body to return to its normal, healthy weight.There are also more serious risks associated with HRT, which include blood clots and developing different types of cancer with long-term use of the medication. The length of taking the hormones is one of the main determining factors that influences which type of side effects may develop.

Outlook on the Protein Therapeutics Global Market to 2026 – by Product, Therapy Area, Function and Region – ResearchAndMarkets.com – Yahoo Finance

DUBLIN, October 18, 2021--(BUSINESS WIRE)--The "Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global protein therapeutics market exhibited moderate growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 6% during 2021-2026.

Companies Mentioned

Amgen Inc.

Abbott Laboratories

Abbvie Inc.

Baxter International Inc.

Biogen Inc.

Csl Behring L.L.C. (CSL Limited)

Eli Lilly and Company

F. Hoffmann-La Roche AG (Roche Holding AG)

Johnson & Johnson

Merck & Co. Inc.

Novo Nordisk A/S (Novo Holdings A/S)

Pfizer Inc.

Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.

Protein therapeutics refers to artificially synthesized protein-based medicines. They are fast-acting, potent medicines that deliver small protein molecules to the body in a specific amount. They usually consist of recombinant forms of naturally occurring proteins, such as monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormones (HGH) and follicle-stimulating hormones. They aid in treating chronic medical ailments, such as cancer, diabetes, neurodegenerative disorders and immunological, hematological, hormonal and genetic disorders. Various combination therapy drugs are also used with protein therapeutics that can be inhaled, injected or orally administered.

The increasing prevalence of chronic medical ailments is one of the key factors driving the growth of the protein therapeutics market. In line with this, the rising awareness among the masses regarding the benefits of protein therapeutics, such as minimal risks of side effects and high efficiency, are contributing to the market growth. Monoclonal antibodies are being widely researched and used for the treatment of various viral and bacterial diseases and pharmaceutical companies are using protein therapeutics for drug discovery and development. The sudden outbreak of the coronavirus disease (COVID-19) is further providing growth opportunities to market players. For instance, Molecular Partners AG, a Switzerland-based clinical stage biotechnology company, is developing a new class of protein therapeutics, called DARPin, to inhibit the proliferation of the virus.

Story continues

The development of novel recombinant proteins, peptides, antibody-based drugs and plasma proteins is acting as other-growth inducing factors. These protein therapeutics are extensively used in replacement therapies to treat genetic and autoimmune disorders, such as dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Other factors, including extensive research and development (R&D) activities in the field of protein engineering, along with significant improvements in the healthcare infrastructure, are expected to drive the market further.

Key Questions Answered in This Report

How has the global protein therapeutics market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global protein therapeutics market?

What are the key regional markets?

What is the breakup of the market based on the product?

What is the breakup of the market based on the therapy area?

What is the breakup of the market based on the function?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global protein therapeutics market and who are the key players?

What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Protein Therapeutics Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product

7 Market Breakup by Therapy Area

8 Market Breakup by Function

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/hbqe91

View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005751/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See more here:

Outlook on the Protein Therapeutics Global Market to 2026 - by Product, Therapy Area, Function and Region - ResearchAndMarkets.com - Yahoo Finance

If we don’t face vaccine facts, the pandemic will continue – The Review Newspaper

People with jobs usually must follow rules in order to keep those jobs. Some of these basic conditions of employment include not using or being impaired by alcohol or drugs while on the job, and abiding by established health and safety rules. But there are some who feel that mandatory COVID-19 vaccinations for health care workers are not part of workplace health and safety.

Employees of Hawkesbury and District General Hospital (HGH) were required to be vaccinated against COVID-19 as of October 15. As of November 15, all long-term care facility employees across Ontario must be vaccinated. Locally, a small but vocal group of vaccine dissenters have been protesting, allegedly in support of health care workers who are losing their jobs because they chose not to be vaccinated. The protesters would have the public believe there are now multitudes of unemployed nurses, technicians, orderlies, and even physicians. Their argument is weak considering that nearly two weeks ago, HGH officials were estimating more than 99 per cent of employees would be vaccinated by the deadline. At the Prescott and Russell Residence, more than 97 per cent of employees at the long-term care facility had been vaccinated as of October 7. With compliance rates like these, so much for the notion of multitudes of unvaccinated nurses applying for Employment Insurance.

Sadly, the protests are about more than the vaccination. It would seem that much of the protest seems to be about the management of the pandemic, and in some cases, the very existence of the pandemic and the severity of the illness associated with COVID-19. Protest signs seemed more about government conspiracies and allegations of COVID-19 vaccines rather than showing support for health care workers.

These activists sometimes describe themselves as defenders of true liberty and conservatism. As protesters question mandated vaccinations, so, too, can the rest of us question the notion of individual liberty versus the common good. Citizens may be free to say no to vaccination, but the consequences of their decision will continue to stretch front-line health care workers to the breaking point. Job losses, economic fragility, the impact on education systems, and mental health challenges will continue to strain society as we wait out the consequences of those who think they are free to say no to a vaccine that is saving lives.

Things will reach a breaking point. While some are encouraging kindness and making allowance for the right to choice, one cannot help but compare the refusal to get vaccinated to the refusal of each of us to take positive action for climate change. As humans, if we know that something is destroying us, why would we not take action to save ourselves? Here, too, climate-action deniers deny science.

The solution is: education and the facts. One has only to look to history to find many examples of attitude change. Think about slavery, Japanese-Canadian internment camps, our treatment of Indigenous peoples, our attitude about tobacco.

It is scary how many mistakes can be found in our past. But more frightening still is how long it takes to change peoples attitudes. We can each do our part to ensure that we are not spreading misinformation, but our governments need to step up their efforts to get good, clear information in front of the people who need to hear it.

We are all in this together. And if we dont get on top of this, we will all go down together. At that point, who was right simply wont matter.

By James Morgan and Louise Sproule

Link:

If we don't face vaccine facts, the pandemic will continue - The Review Newspaper

COVID-19 vaccination rates are higher across the St. Lawrence River, but opposition remains – North Country Public Radio

A demonstration against mandatory COVID-19 vaccination for health care workers in Hawkesbury Ontario, on October 8. Photo: James Morgan

Oct 15, 2021

Canadians with ties to the North Country, or who plan to make the long drive south to warmer weather this winter rejoiced when the news got outearlier this week that land ports of entry to the US would be reopening to fully vaccinated Canadians sometime in November.

The high COVID-19 vaccination rates among residents of eastern Ontario are a positive sign of the low transmission risk among the population. However, opposition to mandatory vaccination for health care workers remains among a minority of residents.

Late last month, Dr. Paula Stewart, the Medical Officer of Health for the Leeds, Grenville, and Lanark District Health Unit, reportedthat 90% of the territorys residents aged 12 and older had been fully vaccinated against COVID-19.The area includes Gananoque, Brockville, Prescott,Kemptville, and Perth.

"This high level of vaccination will reduce the risk of COVID-19 in our community, and prevent hospitalizations and death, said Stewart in a statement.Shecredited the efforts of health care providers, volunteers, and local governments for making vaccination accessible to citizens.

The COVID-19 vaccination rate is lower, but still quite high, further east in the five-county territory served by the Eastern Ontario Health Unit (EOHU). In addition to the villages and rural towns of the United Counties of Stormont, Dundas, and Glengarry, and the United Counties of Prescott and Russell, the EOHUs territory includes Cornwall and the portion of Akwesasne located north of the international border.

As of October 13, 84.9% of residents of the EOHU jurisdiction aged 12 andabove had received two vaccine doses.

By comparison, just across the St. Lawrence River, just 68% of St. Lawrence County residents 18 and over have at least one dose of the vaccine.

Small group protests mandatory vaccination of hospital workers

Despite the high vaccination rates across eastern Ontario, there are still people refusing to be vaccinated, or attempting to politicize mandatory vaccination for hospital and long-term care workers.

On Friday, October 8, a small group of demonstrators in Hawkesbury, located in the northeast corner of the EOHUs territory, protested mandatory COVID-19 vaccination for employees of Hawkesbury and District General Hospital (HGH).

The policy takes effect on Friday, October 15. According to HGH Vice President, Human Resources and Corporate ServicesGiseleLarocque, vaccination will be compulsory for all employees, physicians, learners, and contractors working at HGH. The Ontario Hospital Association has recommended hospitals across the province adopt these policies for the protection of patients and staff.

At the Hawkesbury protest, 31 people carried signs opposing vaccination, mandatory vaccination for hospital employees, claiming that government responses to the pandemic interfere upon personal freedom.

Larocque said HGH published a COVID-19 vaccination policy and informed staff of their obligation to comply on August 26.

As of October 6, the percentage of employees vaccinated is 88.1% for employees and 100% for physicians.

Larocque estimated 99.1% of HGH employees will be vaccinated as of October 15. She said any statistics on possible suspensions or terminations for employees who refuse to be vaccinated is privileged information.

As of October 8, the Ontario government had not made it mandatory for all health care workers across Ontario to be vaccinated against COVID-19. However, Minister of Health Christine Elliott said in the legislature on October 7 the government has not ruled out introducing such a requirement.

The Hawkesbury protesters weredemonstrating approximately half a block away from hospital property. They were notimpeding traffic around the facility. On October 5, John Fraser, a member of the Ontario Legislature from Ottawa,introduced a bill which, if it becomes law, would establish safe zones with a 150-meter (492 feet) radius around hospitals whereprotests would be prohibited.Offenders would face fines ranging from $5,000 $10,000 and up to six months in jail for repeat offences. The bill would no longer be in effect whenever the governments pandemic response laws are repealed or after a two-year period.

On October 1, Ontario Minister of Long-Term Care Rod Phillips announced all employees of long-term care facilities across the province must be vaccinated against COVID-19 by November 15.

The Prescott and Russell Residence is the public long-term care facility operated by the United Counties of Prescott and Russell. Itis located inHawkesbury, not far from where the October 8 protest took place. Administrator Alexandre Gorman estimated that as of October 7, approximately 185 to 190 of 215 to 220 employees at the Residence had received a COVID-19 vaccination. He said vaccination is being addressed with employees who have not yet received their shots, and management will be holding discussions with the individuals. Gorman is hopeful that no staff leave their jobs at the Prescott and Russell Residence over mandatory vaccination.

We hope not, obviously our goal is to keep everyone.

Ascendis Pharma A/S Announces US Commercial Launch of SKYTROFA (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for…

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacies across the United States.

SKYTROFA offers patients, caregivers, and physicians the potential to replace daily somatropin injections that have been the standard of care for more than 30 years, said Jan Mikkelsen, Ascendis Pharmas President and Chief Executive Officer. As the first and only FDA-approved once-weekly therapy for pediatric growth hormone deficiency, SKYTROFA represents one of the most important innovations for these patients in decades.

Reflecting its commitment to patients, Ascendis Pharma has also launched the Ascendis Signature Access Program, a personalized patient support program in the U.S. dedicated to working with families, caregivers, and physicians from decision to treat through long-term therapy adherence. The program is staffed by nurses and offers a full suite of services including, but not limited to, prior authorization support, out of pocket assistance, and training on proper injection procedures.

The full commercial launch of SKYTROFA (lonapegsomatropin-tcgd) marks an important milestone as the Company continues to deliver on its Vision 3x3 strategic roadmap through 2025 to build a leading global biopharma company by achieving sustainable growth through multiple approaches.

The Following Information is Intended for the U.S. Audience Only

INDICATION

SKYTROFA is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).

IMPORTANT SAFETY INFORMATION

You are encouraged to report side effects to FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please click here for full Prescribing Information for SKYTROFA.

About SKYTROFA (lonapegsomatropin-tcgd)SKYTROFA (lonapegsomatropin-tcgd) is a once-weekly prodrug designed to deliver somatropin over a one-week period. The released somatropin has the same 191 amino acid sequence as daily somatropin. SKYTROFA (lonapegsomatropin-tcgd) single-use, prefilled cartridges are available in nine dosage strengths, allowing for convenient dosing flexibility. They are designed for use only with the SKYTROFA Auto-Injector and may be stored at room temperature for up to six months. The recommended dose of SKYTROFA (lonapegsomatropin-tcgd) for treatment-nave patients and patients switching from daily somatropin is 0.24 mg/kg body weight, administered once weekly. The dose may be adjusted based on the childs weight and insulin-like growth factor-1 (IGF-1) SDS.

TransCon hGH (known by its brand name SKYTROFA (Lonapegsomatropin-tcgh) in the U.S.) has been studied in over 300 treatment-naive and treatment-experienced children with GHD across the Phase 3 program, which consists of the heiGHt Trial (for treatment-nave patients), the fliGHt Trial (for treatment-experienced and treatment-naive patients), and the enliGHten Trial (an ongoing long-term open-label extension trial). Patients who completed the heiGHt Trial or the fliGHt Trial were able to continue into the enliGHten Trial, and some have been treated with SKYTROFA (lonapegsomatropin-tcgd) for over four years.TransCon hGH is currently under review by the European Medicines Agency (EMA) in Europe as a potential treatment for pediatric growth hormone deficiency. In addition, TransCon hGH is being evaluated for pediatric GHD in Phase 3 trials in Japan and the Peoples Republic of China, Ascendis Pharma is also conducting the global Phase 3 foresiGHt Trial in adults with GHD. TransCon hGH has been granted orphan designation for GHD in both the U.S. and Europe.

About Ascendis Pharma A/SAscendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit http://www.ascendispharma.com to learn more.

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis use of the Ascendis Signature Access Program to support the use of SKYTROFA (lonapegsomatropin-tcgd) by families, caregivers, and physicians, (ii) Ascendis use of its co-pay as well as a separate assistance program for patients and families facing financial need, (iii) Ascendis ability to apply its platform technology to build a leading, fully integrated biopharma company, and (iv) Ascendis use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers and distributors to supply TransCon hGH, the SKYTROFA Auto-Injector and other study drug for commercial sales in the U.S. and clinical studies; unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to commercialization of lonapegsomatropin-tcgd in the U.S., the co-pay program, and the further development of TransCon hGH, expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis business in general, see Ascendis Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 10, 2021 and Ascendis other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. October 2021 Ascendis Pharma A/S.

Here is the original post:

Ascendis Pharma A/S Announces US Commercial Launch of SKYTROFA (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for...